Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Bart Molemans"'
Autor:
Gaia Kiru, Neil R Poulter, Sarah Bray, Maciej Banach, Katarina Raslova, Alexander Parkhomenko, Dimitrios Tousoulis, Michal Vrablík, Charalambos Vlachopoulos, Helle K. Iversen, Serge Kownator, Róbert Gábor Kiss, Dan Gaita, Bart Molemans, Jacek Jerzy Jozwiak, André Peeters, Periklis Giovas, W. Marieke Schoonen, DA Vinci study, Luis Masana, Stefano De Servi, Piers Clifford, Vincent Maher, Ioanna Gouni-Berthold, Stefano Romeo, Alberico L. Catapano, J. Wouter Jukema, Peter Siostrzonek, G. Kees Hovingh, Jennifer Murphy, Kausik K. Ray
Publikováno v:
European Journal of Preventive Cardiology, 28(11), 1279-1289. OXFORD UNIV PRESS
European journal of preventive cardiology, 28(11), 1279-1289. SAGE Publications Ltd
European journal of preventive cardiology, Vol. 28, no. 11, p. 1279-1289 (2021)
Ray, K K & DA VINCI study 2021, ' EU-Wide Cross-Sectional Observational Study of Lipid-Modifying Therapy Use in Secondary and Primary Care : the DA VINCI study ', European Journal of Preventive Cardiology, vol. 28, no. 11, pp. 1279–1289 . https://doi.org/10.1093/eurjpc/zwaa047
European journal of preventive cardiology, 28(11), 1279-1289. SAGE Publications Ltd
European journal of preventive cardiology, Vol. 28, no. 11, p. 1279-1289 (2021)
Ray, K K & DA VINCI study 2021, ' EU-Wide Cross-Sectional Observational Study of Lipid-Modifying Therapy Use in Secondary and Primary Care : the DA VINCI study ', European Journal of Preventive Cardiology, vol. 28, no. 11, pp. 1279–1289 . https://doi.org/10.1093/eurjpc/zwaa047
Aims To provide contemporary data on the implementation of European guideline recommendations for lipid-lowering therapies (LLTs) across different settings and populations and how this impacts low-density lipoprotein cholesterol (LDL-C) goal achievem
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::26a7f8dc611f9372ae51376e0a17cfab
http://hdl.handle.net/1887/3274109
http://hdl.handle.net/1887/3274109
Autor:
A.L. Catapano, Neil R Poulter, Sarah Bray, Periklis Giovas, Bart Molemans, W.M. Schoonen, Kausik K. Ray
Publikováno v:
Atherosclerosis. 315:e13
Autor:
Stefan D. Anker, Pedro Aljama, Bernard Canaud, Iain C. Macdougall, Kai-Uwe Eckardt, Joseph Kim, Bruno Fouqueray, Elizabeth Ireland, Guntram Schernthaner, Peter Stenvinkel, Bart Molemans, Florian Kronenberg
Publikováno v:
Journal of the American Society of Nephrology. 21:1765-1775
Patients with CKD exhibit significant within-patient hemoglobin (Hb) level variability, especially with the use of erythropoiesis stimulating agents (ESAs) and iron. Analyses of dialysis cohorts in the United States produced conflicting results regar
Autor:
Jürgen, Floege, Joseph, Kim, Elizabeth, Ireland, Charles, Chazot, Tilman, Drueke, Angel, de Francisco, Florian, Kronenberg, Daniele, Marcelli, Jutta, Passlick-Deetjen, Guntram, Schernthaner, Bruno, Fouqueray, David C, Wheeler, Bart, Molemans
Publikováno v:
Nephrology Dialysis Transplantation
Background. A number of US observational studies reported an increased mortality risk with higher intact parathyroid hormone (iPTH), calcium and/or phosphate. The existence of such a link in a European haemodialysis population was explored as part of
Autor:
Fernando Carrera, Dave Carter, Bart Molemans, Andreas Bock, Reinhard Brunkhorst, Michael Iskedjian, Sean Robbins, Xavier Bonafont, Bastian Dehmel
Publikováno v:
NDT Plus
Background. Erythropoiesis-stimulating agents (ESAs) such as epoetin alfa and beta, and darbepoetin alfa have improved the management of anaemia secondary to chronic kidney disease. Numerous studies have reported a dose reduction when patients receiv
Autor:
Peter Stenvinkel, Bart Molemans, Florian Kronenberg, K.-U. Eckardt, Stefan D. Anker, Angel L.M. de Francisco, Guntram Schernthaner, David C. Wheeler, Vasily Belozeroff, Joseph Kim, Iain C. Macdougall, Jürgen Floege, Tilman B. Drüeke, Charles Chazot, Bernard Canaud, Pedro Aljama, Bruno Fouqueray, Jutta Passlick-Deetjen, Daniele Marcelli
Publikováno v:
Nephron. Clinical practice. 118(2)
Background/Aims: ARO, an observational study of hemodialysis (HD) patients in Europe, aims to enhance our understanding of patient characteristics and practice patterns to improve patient outcome. Methods: HD patients (n = 8,963) from 134 Fresenius M